Trial Profile
DARZALEX intravenous drip infusion 100 mg, 400 mg Special Drug Use Results Survey (Recurrent or refractory multiple myeloma)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2022
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 12 Aug 2020 Status changed from recruiting to active, no longer recruiting.
- 12 Feb 2018 New trial record